Shares in Seattle biotech firm Omeros shot up more than 60% Monday after a preliminary trial suggested the company's new drug, narsoplimab, could boost survival rates for COVID-19 patients on respirators.
source https://www.seattletimes.com/seattle-news/health/promising-covid-19-treatment-sends-seattle-biotech-companys-stock-soaring/?utm_source=RSS&utm_medium=Referral&utm_campaign=RSS_technology
No comments:
Post a Comment